芪骨胶囊联合碳酸钙D3治疗原发性骨质疏松症41例疗效观察

目的:探讨芪骨胶囊联合碳酸钙D₃对原发性骨质疏松症患者腰背部疼痛及骨密度的影响。方法:选择2018年2月至2020年2月期间江西中医药大学附属洪都中医院收治的原发性骨质疏松症患者82例,采用随机数字表法分为对照组与观察组各41例。对照组口服碳酸钙D₃(钙尔奇D₃)片,观察组在对照组基础上加用芪骨胶囊。比较两组治疗效果、腰背部疼痛、骨密度及安全性。结果:观察组治疗总有效率(95.12%)高于对照组(78.05%);腰背部疼痛评分低于对照组;骨密度之腰椎(0.659±0.124)g/cm²、股骨颈(0.654±0.137)g/cm²,均高于对照组的(0.573±0.087)g/cm²、(0.578±0.074)g/cm²,均差异有统计学意义(P<0.05)。治疗期间两组均未发生严重不良反应。结论:原发性骨质疏松症患者采用芪骨胶囊联合碳酸钙D₃治疗效果显著,利于改善患者疼痛程度,提高骨密度,且不良反应较少。

Effect of Qigu Capsule Combined with Caltrate D3 on 41 Cases of Primary Osteoporosis

Objective:To investigate the effect of Qigu capsule combined with Caltrate D₃ on back pain and bone mineral density in patients with primary osteoporosis.Methods:82 patients with primary osteoporosis in Hongdu Hospital of Traditional Chinese Medicine Affiliated to Jiangxi University of Traditional Chinese Medicine from February 2018 to February 2020 were selected and randomly divided into control group and observation group with 41 cases in each group.The control group was treated with Caltrate D₃ tablets,and the observation group was treated with Qigu Capsule on the basis of the control group.The therapeutic effect,back pain,bone mineral density and safety of the two groups were compared.Results:The total effective rate of treatment in the observation group(95.12%)was higher than that of the control group(78.05%),the lower back pain score was lower than that of the control group,lumbar spine(0.659±0.124)g/cm²,femoral neck(0.654±0.137)g/cm²,Both were higher than the control group(0.573±0.087)g/cm²,(0.578±0.074)g/cm²,the difference was statistically significant(P<0.05).No serious adverse reactions occurred in the two groups during the treatment.Conclusion:The therapeutic effect of Qigu capsule combined with Caltrate D₃ in patients with primary osteoporosis is significant,which is beneficial to improve the pain degree and bone density of the patients,and has fewer adverse reactions.